Treatment of Delayed Pulmonary Transition in Extremely Preterm Infants & Bronchopulmonary Dysplasia

1170748

Inhaled nitric oxide (iNO) is an effective treatment for pulmonary hypertension (PH) in term and near-term infants. Preterm infants are at risk for early PH that is associated with high risk for bronchopulmonary dysplasia or death. In multiple clinical trials, iNO treatment was not effective for BPD prevention. However, infants were not screened for PH and iNO treatment was not targeted for PH. iNO treatment for PH in preterm infants is controversial due to lack of evidence. The study team hypothesizes that early diagnosis of PH (72-96 hours of life) and iNO treatment will decrease the incidence of death and bronchopulmonary dysplasia and improve oxygenation in extremely preterm infants. 1. To determine if iNO treatment of extremely preterm infants with early pulmonary hypertension as established with echocardiographic evidence at 72-96 hours of age will decrease incidence of death or BPD. 2. To determine if iNO treatment of extremely preterm infants with early PH will decrease the pulmonary artery pressure and improve oxygenation within 72 hours of intervention.

2019-07-15

2024-12-01

2024-12-01

Recruiting

Early phase I

138

Inclusion Criteria: Step 1: * Birth between 23 weeks and 0 days and 29 weeks and 6 days. * Positive pressure ventilation at 72-96 hours of age Step 2: * Early pulmonary hypertension Exclusion Criteria: Step 1: * Death prior to 12 hours of age or first echocardiogram * Chromosomal anomalies * Major congenital anomalies * Myocardial dysfunction * Complex cardiac defect * Dependent on right to left shunting of blood Step 2: * Excessive pulmonary blood flow (left to right shunt across PDA) * Pulmonary blood flow obstruction secondary to pulmonary vein stenosis * Mitral valve stenosis * Cor triata * Aortic valve atresia

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Masked randomized controlled trial', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 138, 'type': 'ESTIMATED'}}

2023-06-29